IRIS
PANICHELLA, GIORGIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.367
AS - Asia 3.705
EU - Europa 3.569
SA - Sud America 749
AF - Africa 92
Continente sconosciuto - Info sul continente non disponibili 78
OC - Oceania 8
Totale 12.568
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.085
IT - Italia 1.531
SG - Singapore 1.328
CN - Cina 935
RU - Federazione Russa 855
BR - Brasile 584
VN - Vietnam 444
BD - Bangladesh 330
HK - Hong Kong 214
NL - Olanda 167
GB - Regno Unito 163
CA - Canada 159
IE - Irlanda 158
DE - Germania 157
FR - Francia 115
FI - Finlandia 107
IN - India 87
SE - Svezia 76
TR - Turchia 74
PL - Polonia 64
MX - Messico 63
AR - Argentina 61
PK - Pakistan 44
ES - Italia 36
ID - Indonesia 36
IQ - Iraq 36
EC - Ecuador 34
ZA - Sudafrica 32
IL - Israele 31
JP - Giappone 30
AT - Austria 26
CO - Colombia 25
UZ - Uzbekistan 21
UA - Ucraina 20
MA - Marocco 16
CH - Svizzera 15
EG - Egitto 13
LT - Lituania 13
BE - Belgio 12
AE - Emirati Arabi Uniti 11
CL - Cile 11
VE - Venezuela 11
PH - Filippine 10
SA - Arabia Saudita 10
MY - Malesia 9
RO - Romania 9
HN - Honduras 8
JM - Giamaica 8
KE - Kenya 8
PT - Portogallo 8
PY - Paraguay 8
PE - Perù 7
TN - Tunisia 7
AU - Australia 6
CR - Costa Rica 6
GT - Guatemala 6
NP - Nepal 6
TT - Trinidad e Tobago 6
DZ - Algeria 5
JO - Giordania 5
KR - Corea 5
KZ - Kazakistan 5
NI - Nicaragua 5
OM - Oman 5
SK - Slovacchia (Repubblica Slovacca) 5
BY - Bielorussia 4
DK - Danimarca 4
GR - Grecia 4
SV - El Salvador 4
UY - Uruguay 4
AL - Albania 3
AZ - Azerbaigian 3
BO - Bolivia 3
CG - Congo 3
DO - Repubblica Dominicana 3
KW - Kuwait 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
GD - Grenada 2
HR - Croazia 2
IR - Iran 2
KH - Cambogia 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
PR - Porto Rico 2
PS - Palestinian Territory 2
QA - Qatar 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AD - Andorra 1
AG - Antigua e Barbuda 1
BH - Bahrain 1
BZ - Belize 1
CU - Cuba 1
CV - Capo Verde 1
Totale 12.467
Salva come PNG Salva come JPEG
Città #
Dallas 808
Singapore 724
San Jose 492
Ashburn 411
Beijing 325
Council Bluffs 267
Hong Kong 192
Los Angeles 170
Milan 158
Moscow 157
Dublin 155
Ho Chi Minh City 147
New York 128
Rome 108
Hanoi 101
Santa Clara 90
Helsinki 73
Phoenix 66
Pisa 65
São Paulo 63
Chandler 60
Florence 59
The Dalles 59
Lauterbourg 54
Warsaw 54
Hefei 53
Munich 49
Naples 47
Istanbul 45
Montreal 45
Orem 40
Buffalo 38
Bologna 37
Amsterdam 36
London 36
Boardman 35
Da Nang 34
Frankfurt am Main 34
Mexico City 34
Turin 33
Chicago 32
Atlanta 30
Beauharnois 29
Lucca 28
Brooklyn 27
Genoa 27
Tokyo 27
Rio de Janeiro 26
Toronto 26
Boston 24
Lappeenranta 24
Nuremberg 24
Poplar 24
Stockholm 24
Tel Aviv 23
Chennai 22
Seattle 22
Denver 21
Johannesburg 21
Brescia 20
Livorno 20
Washington 20
Houston 19
Figino 18
Palermo 17
Tashkent 17
Belo Horizonte 15
Hyde Park 15
Lahore 15
Manchester 15
Verona 15
Haiphong 14
Mumbai 14
Charlotte 13
Guayaquil 13
Quito 13
Shenzhen 13
Assago 12
Curitiba 12
Paris 12
Bari 11
Biên Hòa 11
Querétaro 11
Redondo Beach 11
Baghdad 10
Cagliari 10
Cambridge 10
Catania 10
Columbus 10
Dhaka 10
Ottawa 10
San Mateo 10
Vienna 10
Brasília 9
Kochi 9
Portsmouth 9
Suzhou 9
Turku 9
Zhengzhou 9
Ankara 8
Totale 6.581
Salva come PNG Salva come JPEG
Nome #
Left ventricular outflow tract velocity-time integral improves outcome prediction in patients with secondary mitral regurgitation 641
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 478
The Fondazione Toscana Gabriele Monasterio app: a digital health system to improve wellbeing of inpatients with heart or lung disease 354
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 345
Eligibility for vericiguat in a real‐world, contemporary heart failure population 318
Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis 313
Echocardiography-Derived Forward Left Ventricular Output Improves Risk Prediction in Systolic Heart Failure 306
Screening the health status of people working in a university 303
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 303
RNA-targeting and gene editing therapies for transthyretin amyloidosis 301
Big gamma-glutamyltransferase is associated with epicardial fat volume and cardiovascular outcome in the general population 286
Assessing cardiac mechanics through left ventricular haemodynamic forces 257
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 255
Role of Imaging in Cardiomyopathies 252
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 252
Valvular heart disease in patients with cardiac amyloidosis 244
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 237
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 235
Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review 227
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 226
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 224
Cardiac Amyloidosis: How Its Epidemiology is Changing 223
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis 222
Subclinical cardiac damage in cancer patients before chemotherapy 218
Bridging Atrial and Ventricular Failure Through Biomarkers 217
The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population 212
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 212
Sex-related differences in ventricular remodeling after myocardial infarction 212
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 210
High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis 207
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction 200
Sex differences in transthyretin cardiac amyloidosis 195
Echocardiographic Estimate of Pulmonary Capillary Wedge Pressure Improves Outcome Prediction in Heart Failure Patients with Reduced and Mildly Reduced Ejection Fraction 192
Pathophysiology of Cardiac Amyloidosis 189
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 189
Gamma-glutamyltransferase independently predicts mortality and hospitalization for heart failure in cardiac transthyretin amyloidosis 189
Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity 189
Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review 187
The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers 186
Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease 177
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism 175
Heart failure with preserved ejection fraction risk after aortic coarctation surgery: The hidden threat 172
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin 168
CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis 167
Dissecting the heart failure phenotype through phenomics 153
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 151
Metabolomics to predict heart failure development: A new frontier? 149
Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift 133
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond 132
Pirfenidone as a novel cardiac protective treatment 130
Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy 128
Insulin‐like growth factor binding protein‐7 in heart failure: The challenge of moving from risk prediction to a biomarker‐guided management 127
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up 122
Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It? 121
Changes in CMR-derived ventricular strain, fibrosis progression and outcomes in hypertrophic cardiomyopathy 91
Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It? 61
The evolving role of metabolic and bariatric surgery in contemporary clinical practice 54
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 47
PAWP vs LVEDP During Invasive Cardiopulmonary Exercise Testing: In Search of the Holy Grail of a Hemodynamic Truth in Heart Failure. 45
Therapy of amyloidosis: stabilizers and silencers 30
Event rates in major Phase 3 heart failure trials over the last 20 years 29
Totale 12.568
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.748
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.748
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202266 0 0 0 5 7 7 10 17 7 6 2 5
2022/2023367 5 28 10 21 44 40 14 47 109 10 27 12
2023/2024333 13 11 63 36 7 25 27 13 15 26 28 69
2024/20252.734 71 68 134 108 184 154 383 539 286 145 358 304
2025/20267.971 421 1.059 740 1.119 785 547 737 453 520 533 568 489
2026/20271.097 256 257 476 108 0 0 0 0 0 0 0 0
Totale 12.568